pharma in focus 28 Aug- 1 Sept 2023
Posted 28 August 2023
Offering innovative but costly therapies is a major dilemma faced by Australian oncologists with a new survey finding they fear putting their patients under financial stress.
The survey, conducted by Servier Laboratories, aimed to unpack the barriers to cancer clinicians offering new therapies that are not available on the PBS to their patients.
While pharmaceutical companies often step in with a level of discount, known as co-pay programs, it still means considerable out of pocket costs for the patient. Only 10 per cent of the respondents said that they felt ‘comfortable’ raising the subject.
Private Cancer Physicians of Australia (PCPA) members, including radiologists, medical oncologists, and haematologist specialists were among respondents.